Skip to content
The Nexus
DossierENTITY

Biktarvy

Coverage of Biktarvy in the Nexus archive.

Earliest in view: Jul 14 · 19:57 UTCMost recent: Jul 14 · 19:57 UTC
Co-mentioned in this coverage
340B drug discount programtopic1Health Resources and Services Administrationorganization1Merckorganization1Keytrudatopic1Gilead Sciencesorganization1
Recent coverage
  • HEALTHJul 14 · 19:57 UTCSTAT NEWS
    STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year

    Sales under the U.S. 340B Drug Discount Program reached $100 billion in 2025, a 22.8% increase from the previous year. Expensive medicines accounted for 62% of spending, with Merck’s Keytruda and Gilead Sciences’ Biktarvy being the top two drugs by spending. The program requires drugmakers to offer 25-50% discounts to hospitals and clinics serving lower-income patients.

Biktarvy · Dossier · The Nexus